The clinical profile of NMOSD in Australia and New Zealand
Neuromyelitis optica spectrum disorders (NMOSD) are an inflammation of the central nervous system associated with autoantibodies to aquaporin-4. We have undertaken a clinic-based survey of NMOSD in the Australia and New Zealand populations with the aim of characterising the clinical features and est...
Автори: | Bukhari, W, Clarke, L, O'Gorman, C, Khalilidehkordi, E, Arnett, S, Prain, KM, Woodhall, M, Silvestrini, R, Bundell, CS, Ramanathan, S, Abernethy, D, Bhuta, S, Blum, S, Boggild, M, Boundy, K, Brew, BJ, Brownlee, W, Butzkueven, H, Caroll, WM, Chen, C, Coulthard, A, Dale, RC, Das, C, Dear, K, Fabis-Pedrini, MJ, Fulcher, D, Gillis, D, Hawke, S, Heard, R, Henderson, APD, Heshmat, S, Hodgkinson, S, Jimenez-Sanchez, S, Kilpatrick, TJ, King, J, Kneebone, C, Kornberg, AJ, Lechner-Scott, J, Lin, M-W, Lynch, C, MacDonnell, RAL, Mason, DF, McCombe, PA, Pereira, J, Pollard, JD, Reddel, SW, Shaw, C, Spies, J, Stankovich, J, Sutton, I, Vucic, S, Walsh, M, Wong, RC, Yiu, EM, Barnett, MH, Kermode, AG, Marriott, MP, Parratt, J, Slee, M, Taylor, BV, Willoughby, E, Wilson, RJ, Brilot, F, Vincent, A, Waters, P, Broadley, SA |
---|---|
Формат: | Journal article |
Мова: | English |
Опубліковано: |
Springer Verlag
2020
|
Схожі ресурси
Схожі ресурси
-
Incidence and prevalence of NMOSD in Australia and New Zealand
за авторством: Bukhari, W, та інші
Опубліковано: (2017) -
AQP4 antibody assay sensitivity comparison in the era of the 2015 diagnostic criteria for NMOSD
за авторством: Prain, K, та інші
Опубліковано: (2019) -
Relapse Patterns in NMOSD: Evidence for Earlier Occurrence of Optic Neuritis and Possible Seasonal Variation
за авторством: Elham Khalilidehkordi, та інші
Опубліковано: (2020-06-01) -
AQP4 Antibody Assay Sensitivity Comparison in the Era of the 2015 Diagnostic Criteria for NMOSD
за авторством: Kerri Prain, та інші
Опубліковано: (2019-10-01) -
Characterization of NMO and NMOSD Patients with a Late Onset
за авторством: Collongues, N, та інші
Опубліковано: (2013)